SCT and OMT Announce Human Antibody Discovery and Development Collaboration
News Dec 04, 2012
Single Cell Technology, Inc. (SCT) and Open Monoclonal Technology, Inc. (OMT) have announced a new collaboration where OMT will use its OmniRat™ transgenic animal platform to generate human antibodies against a therapeutic target identified by SCT.
SCT will utilize its patented platform to massively screen plasma cells, measure the kinetics of secreted antibodies, and sequence the cognate light and heavy chain mRNA powered by Next Generation Sequencing (NGS).
SCT will advance and partner the program and share the economics with OMT depending on the stage of development. SCT will also have an option to develop and commercialize selected products resulting from the research.
Dr. Chun-Nan Chen, Founder and CEO of SCT said: “This partnership with OMT will demonstrate the value of delineating the antibody repertoire of the humoral response by NGS early during antibody discovery. The human immune gene sequences engineered into OmniRat by OMT will work perfectly with SCT’s massive screening and sequencing platform. We anticipate exciting results.”
Dr. Roland Buelow, Founder and CEO of OMT, continued: "We are pleased to collaborate with SCT to capture the synergies of our complementary antibody discovery technologies. This collaboration continues OMT’s process of participating in as many opportunities for development of human therapeutic antibodies as possible and establishing OmniRat as a leading transgenic animal brand.”
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Alternative to Antibiotics: Antibody Approach for Treating Multidrug-Resistant Bacterial InfectionsNews
Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide.READ MORE
Comments | 0 ADD COMMENT
7th International Conference on Bacteriology and Infectious Diseases
Jun 04 - Jun 05, 2018